320
Views
17
CrossRef citations to date
0
Altmetric
Original Articles

Second Generation of cycloSal‐Pronucleotides with Esterase‐Cleavable Sites: The ”Lock‐In”‐Concept

, , &
Pages 89-115 | Received 31 Jul 2003, Accepted 19 Sep 2003, Published online: 01 Jun 2007
 

Abstract

A conceptual extension of the cycloSal‐pronucleotide approach is presented. The characteristic feature of the new cycloSal‐derivatives of the anti‐HIV active nucleoside analogue d4T 1 is the incorporation of an enzymatically cleavable carboxylic ester moiety with the intention to trap the triesters inside cells (”lock‐in”‐concept). CycloSal‐triesters bearing different ester groups in the 3‐or 5‐position of the cycloSal‐moiety are described. Surprisingly, only acetyl‐and levulinyl esters are cleaved readily in CEM cell extracts while alkyl esters were found to be stable. Nevertheless, in in‐vitro anti‐HIV assays most of the compounds achieve the thymidine–kinase bypass, thus proving that they act at least as nucleotide delivery systems.

In honor and celebration of the 70th birthday of Professor Leroy B. Townsend.

Acknowledgments

Financial support by the Deutsche Forschungsgemeinschaft, Germany, the Fonds der Chemischen Industrie, Germany and the René Descartes Prize 2001 of the European Commission is gratefully acknowledged.

Notes

In honor and celebration of the 70th birthday of Professor Leroy B. Townsend.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.